Illustration: Aïda Amer/Axios
The FDA on Wednesday approved Revolution Medicines' pancreatic cancer drug Rasonque, which nearly doubled overall survival in a clinical trial.
Why it matters: The milestone could put Revolution back on buyers' radars while validating RAS as a commercial drug category.
